Sarepta Therapeutics Asset Turnover Growth & History (SRPT)
Sarepta Therapeutics's asset turnover was 0.51 for fiscal 2025.
View full Sarepta Therapeutics company overviewSarepta Therapeutics annual asset turnover history
| Fiscal year | Period ended | Asset turnover | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.51 | 0.02 | +3.06% |
| 2024 | 2024-12-31 | 0.49 | 0.14 | +38.13% |
| 2023 | 2023-12-31 | 0.36 | 0.09 | +33.21% |
| 2022 | 2022-12-31 | 0.27 | 0.07 | +34.63% |
| 2021 | 2021-12-31 | 0.20 | 0.01 | +5.31% |
| 2020 | 2020-12-31 | 0.19 | −0.03 | −13.73% |
| 2019 | 2019-12-31 | 0.22 | 0.02 | +7.71% |
| 2018 | 2018-12-31 | 0.20 | 0.03 | +14.34% |
| 2017 | 2017-12-31 | 0.18 | 0.16 | +1048.96% |
| 2016 | 2016-12-31 | 0.02 | 0.01 | +252.63% |
| 2015 | 2015-12-31 | 0.00 | −0.03 | −86.76% |
| 2014 | 2014-12-31 | 0.03 | −0.02 | −41.91% |
| 2013 | 2013-12-31 | 0.06 | −0.23 | −80.10% |
| 2012 | 2012-12-31 | 0.29 | −0.65 | −69.27% |
| 2011 | 2011-12-31 | 0.94 | — | — |
Sarepta Therapeutics quarterly asset turnover
| Fiscal quarter | Period ended | Asset turnover | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.43 | −0.19 | −31.19% |
| Q1 2026 | 2026-03-31 | 0.50 | −0.12 | −19.04% |
| Q4 2025 | 2025-12-31 | 0.53 | 0.03 | +5.91% |
| Q3 2025 | 2025-09-30 | 0.61 | 0.16 | +34.44% |
| Q2 2025 | 2025-06-30 | 0.62 | 0.20 | +46.32% |
| Q1 2025 | 2025-03-31 | 0.62 | 0.21 | +52.05% |
| Q4 2024 | 2024-12-31 | 0.50 | 0.14 | +39.70% |
| Q3 2024 | 2024-09-30 | 0.45 | 0.13 | +39.28% |
| Q2 2024 | 2024-06-30 | 0.43 | 0.13 | +42.58% |
| Q1 2024 | 2024-03-31 | 0.41 | 0.12 | +39.75% |
| Q4 2023 | 2023-12-31 | 0.36 | 0.09 | +33.21% |
| Q3 2023 | 2023-09-30 | 0.32 | 0.05 | +19.91% |
| Q2 2023 | 2023-06-30 | 0.30 | 0.04 | +15.25% |
| Q1 2023 | 2023-03-31 | 0.29 | 0.06 | +24.76% |
| Q4 2022 | 2022-12-31 | 0.27 | 0.07 | +34.63% |
| Q3 2022 | 2022-09-30 | 0.27 | 0.07 | +32.26% |
| Q2 2022 | 2022-06-30 | 0.26 | 0.08 | +43.09% |
| Q1 2022 | 2022-03-31 | 0.23 | 0.06 | +38.16% |
| Q4 2021 | 2021-12-31 | 0.20 | 0.01 | +5.31% |
| Q3 2021 | 2021-09-30 | 0.20 | 0.01 | +5.74% |
| Q2 2021 | 2021-06-30 | 0.18 | 0.00 | +2.03% |
| Q1 2021 | 2021-03-31 | 0.17 | 0.01 | +4.74% |
| Q4 2020 | 2020-12-31 | 0.19 | −0.03 | −13.73% |
| Q3 2020 | 2020-09-30 | 0.19 | −0.06 | −23.62% |
| Q2 2020 | 2020-06-30 | 0.18 | −0.05 | −22.87% |
| Q1 2020 | 2020-03-31 | 0.16 | −0.04 | −18.98% |
| Q4 2019 | 2019-12-31 | 0.22 | 0.02 | +7.71% |
| Q3 2019 | 2019-09-30 | 0.25 | −0.02 | −8.37% |
| Q2 2019 | 2019-06-30 | 0.23 | −0.05 | −19.09% |
| Q1 2019 | 2019-03-31 | 0.20 | −0.03 | −11.49% |
| Q4 2018 | 2018-12-31 | 0.20 | 0.03 | +14.34% |
| Q3 2018 | 2018-09-30 | 0.28 | 0.12 | +73.11% |
| Q2 2018 | 2018-06-30 | 0.28 | — | — |
| Q1 2018 | 2018-03-31 | 0.22 | — | — |
| Q4 2017 | 2017-12-31 | 0.18 | — | — |
| Q3 2017 | 2017-09-30 | 0.16 | — | — |
| Q4 2014 | 2014-12-31 | 0.03 | −0.02 | −41.91% |
| Q3 2014 | 2014-09-30 | 0.04 | −0.07 | −62.57% |
| Q2 2014 | 2014-06-30 | 0.06 | −0.14 | −70.00% |
| Q1 2014 | 2014-03-31 | 0.07 | −0.19 | −73.50% |
| Q4 2013 | 2013-12-31 | 0.06 | −0.23 | −80.10% |
| Q3 2013 | 2013-09-30 | 0.11 | — | — |
| Q2 2013 | 2013-06-30 | 0.20 | — | — |
| Q1 2013 | 2013-03-31 | 0.25 | — | — |
| Q4 2012 | 2012-12-31 | 0.29 | — | — |
Sarepta Therapeutics asset turnover trends
Over the last five fiscal years, Sarepta Therapeutics's asset turnover increased from 0.19 to 0.51, a change of 0.32. The latest reported quarter, Q2 2026, shows 0.43.
What asset turnover means
Asset turnover measures how much revenue a company generates for each unit of assets employed in the business. A higher ratio generally indicates more efficient asset use, although useful comparisons depend heavily on the industry.
How asset turnover is calculated
TickerStat calculates annual asset turnover as reported revenue divided by average total assets. Quarterly values use trailing-12-month revenue and average assets over the corresponding one-year period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sarepta Therapeutics source filings ↗Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...